Similar Articles
101
Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
102
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy
103
Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
104
Multi-clustering study on the association between human leukocyte antigen
-DP-DQ
and hepatitis B virus-related hepatocellular carcinoma and cirrhosis in Viet Nam
105
Evaluating microvascular invasion in hepatitis B virus-related hepatocellular carcinoma based on contrast-enhanced computed tomography radiomics and clinicoradiological factors
106
Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients
107
Benefits and drawbacks of radiofrequency ablation
via
percutaneous or minimally invasive surgery for treating hepatocellular carcinoma
108
Unlocking the diagnostic potential of vascular endothelial growth factor and interleukin-17: Advancing early detection strategies for hepatocellular carcinoma
109
Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease
110
Lenvatinib, sintilimab combined interventional treatment
vs
bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma
Page 11 of 175 ( 1742 items )
<<
1
...
7
8
9
10
11
12
13
14
...
175
>>
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA